Sale disclosed
David Joseph Gaffin
EVP, CLO, Alkermes, Inc.
Ordinary Shares
- Reported value
- $83.46K
- Reported price
- $41.03 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Alkermes plc.
Last 30 daysNo qualifying insider buying. Sales: $83.46K by 1 insider.
Showing the first 6 of 20 trades on this page.
EVP, CLO, Alkermes, Inc.
Ordinary Shares
EVP, CLO, Alkermes, Inc.
Ordinary Shares
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
EVP R&D, Chief Medical Officer
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
EVP R&D, Chief Medical Officer
Employee Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
SVP, Chief Commercial Officer
Ordinary Shares
SVP, Chief Commercial Officer
Ordinary Shares
President & CEO, Alkermes plc
Employee Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
President & CEO, Alkermes plc
Employee Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Ordinary Shares
Director
Ordinary Shares
Director
Ordinary Shares
Director
Non Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Director
Non Qualified Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP R&D, Chief Medical Officer
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
EVP R&D, Chief Medical Officer
Ordinary Shares
EVP R&D, Chief Medical Officer
Employee Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP R&D, Chief Medical Officer
Employee Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP, CLO, Alkermes, Inc.
Ordinary Shares
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$41.03 / share | $83.46K | Oct 2Filed Oct 2 · 0d later | SEC filing |
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$48.01 / share | $97.65K | Sep 3Filed Sep 3 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesOption exercise or conversion10b5-1 | 5,000$24.59 / share | $122.95K | Sep 1Filed Sep 1 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesSale10b5-1 | 9,000$46.99 / share | $422.87K | Sep 1Filed Sep 1 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Employee Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units5,000$24.59 exercise / conversion price | Not a separate purchase | Sep 1Filed Sep 1 · 0d later | SEC filing |
| SVP, Chief Commercial Officer | Ordinary SharesSale10b5-12 trades | 7,576avg $49.23 / share | $372.94K | Aug 17Filed Aug 17 · 0d later | 2 filings
|
| President & CEO, Alkermes plc | Employee Stock Option (Right to Buy)Grant or award | Derivative units93,229Award · no purchase price | Non-cash award | Aug 5Filed Aug 7 · 2d later | SEC filing |
| President & CEO, Alkermes plc | Employee Stock Option (Right to Buy)Grant or award | Derivative units124,305Award · no purchase price | Non-cash award | Aug 5Filed Aug 7 · 2d later | SEC filing |
| Director | Ordinary SharesOption exercise or conversion | 27,948$46.72 / share | $1.31M | Aug 3Filed Aug 3 · 0d later | SEC filing |
| Director | Ordinary SharesOption exercise or conversion | 16,524$46.72 / share | $772K | Aug 3Filed Aug 3 · 0d later | SEC filing |
| Director | Ordinary SharesSale | 44,472$50.35 / share | $2.24M | Aug 3Filed Aug 3 · 0d later | SEC filing |
| Director | Non Qualified Stock Option (Right to Buy)Option exercise or conversion | Derivative units27,948$46.72 exercise / conversion price | Not a separate purchase | Aug 3Filed Aug 3 · 0d later | SEC filing |
| Director | Non Qualified Stock Option (Right to Buy)Option exercise or conversion | Derivative units16,524$46.72 exercise / conversion price | Not a separate purchase | Aug 3Filed Aug 3 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesOption exercise or conversion10b5-1 | 104$19.34 / share | $2.01K | Aug 3Filed Aug 3 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesOption exercise or conversion10b5-1 | 4,896$24.59 / share | $120.39K | Aug 3Filed Aug 3 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Ordinary SharesSale10b5-1 | 9,000$48.58 / share | $437.22K | Aug 3Filed Aug 3 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Employee Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units104$19.34 exercise / conversion price | Not a separate purchase | Aug 3Filed Aug 3 · 0d later | SEC filing |
| EVP R&D, Chief Medical Officer | Employee Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units4,896$24.59 exercise / conversion price | Not a separate purchase | Aug 3Filed Aug 3 · 0d later | SEC filing |
| EVP, CLO, Alkermes, Inc. | Ordinary SharesSale10b5-1 | 2,034$48.58 / share | $98.81K | Aug 3Filed Aug 3 · 0d later | SEC filing |
Showing the latest 20 of 90 trades. Show all 90 trades
Alkermes plc - Ordinary Shares (ALKS) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House member